Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 257

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

Open access
Ji, Hongbin, Zhao, Xiaojun, Yuza, Yuki, Shimamura, Takeshi, Li, Danan, Protopopov, Alexei, Jung, Boonim L., McNamara, Kate, Xia, Huili, Glatt, Karen A., Thomas, Roman K., Sasaki, Hidefumi, Horner, James W., Eck, Michael, Mitchell, Albert, Sun, Yangping, Al-Hashem, Ruqayyah, Bronson, Roderick T., Rabindran, Sridhar K., Discafani, Carolyn M., Maher, Elizabeth, Shapiro, Geoffrey I., Meyerson, Matthew, Wong, Kwok-Kin·2006·Proceedings of the National Academy of Sciences

Abstract

The tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva) have shown anti-tumor activity in the treatment of non-small cell lung cancer (NSCLC). Dramatic and durable responses have occurred in NSCLC tumors with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). In contrast, these inhibitors have shown limited efficacy in glioblastoma, where a distinct EGFR mutation, the variant III (vIII) in-frame deletion of exons 2–7, is commonly found. In this study, we determined that EGFRvIII mutation was present in 5% (3/56) of analyzed human lung squamous cell carcinoma (SCC) but was not present in human lung adenocarcinoma (0/123). We analyzed the role of the EGFRvIII mutation in lung tumorigenesis and its response to tyrosine kinase inhibition. Tissue-specific expression of EGFRvIII in the murine lung led to the development of NSCLC. Most importantly, these lung tumors depend on EGFRvIII expression for maintenance. Treatment with an irreversible EGFR inhibitor, HKI-272, dramatically reduced the size of these EGFRvIII-driven murine tumors in 1 week. Similarly, Ba/F3 cells transformed with the EGFRvIII mutant were relatively resistant to gefitinib and erlotinib in vitro but proved sensitive to HKI-272. These findings suggest a therapeutic strategy for cancers harboring the EGFRvIII mutation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0510284103

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 257

Metadata

Authors
Ji, H., Zhao, X., Yuza, Y., Shimamura, T., Li, D., Protopopov, A., Jung, B. L., McNamara, K., Xia, H., Glatt, K. A., Thomas, R. K., Sasaki, H., Horner, J. W., Eck, M., Mitchell, A., Sun, Y., Al-Hashem, R., Bronson, R. T., Rabindran, S. K., Discafani, C. M., Maher, E., Shapiro, G. I., Meyerson, M., & Wong, K.-K.
Venue
Proceedings of the National Academy of Sciences
Published
2006-05-16
Volume
103
Issue
20
Pages
7817-7822
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2131351052
Cited by
257
References
36
FWCI
24.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. https://app.cochat.ai/papers/10.1073/pnas.0510284103
The paper
Ji, H., Zhao, X., Yuza, Y., Shimamura, T., Li, D., Protopopov, A., Jung, B. L., McNamara, K., Xia, H., Glatt, K. A., Thomas, R. K., Sasaki, H., Horner, J. W., Eck, M., Mitchell, A., Sun, Y., Al-Hashem, R., Bronson, R. T., Rabindran, S. K., . . . Wong, K.-K. (2006). Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0510284103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.